Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Oct 27, 2023; 15(10): 2272-2279
Published online Oct 27, 2023. doi: 10.4240/wjgs.v15.i10.2272
Endoscopic retrograde cholangiopancreatography for diagnosing and treating pediatric biliary and pancreatic diseases
Xiu-Min Qin, Fei-Hong Yu, Chuan-Kai Lv, Zhi-Min Liu, Jie Wu
Xiu-Min Qin, Fei-Hong Yu, Jie Wu, Department of Gastroenterology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
Chuan-Kai Lv, Department of Ultrasound, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
Zhi-Min Liu, Department of Radiology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
Author contributions: Qin XM, Wu J, Yu FH proposed the concept of this study; Wu J and Liu ZM made contributions to data collection; Lv CK and Yu FH contributed to formal analysis; Qin XM, Liu ZM, Wu J, Yu FH participated in the study; Wu J contributed to the methods; Qin XM, Liu ZM, Wu J guided the research; Wu J and Qin XM validated the effectiveness of this study; Yu FH and Qin XM contributed to the visualization of this study; Qin XM and Wu J drafted the first draft; Yu FH, Liu ZM, Lv CK jointly reviewed and edited the manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Beijing Children’s Hospital Affiliated to Capital Medical University of the National Children’s Medical Center.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie Wu, MD, Chief Doctor, Department of Gastroenterology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, No. 56 Nanlishi Road, Xicheng District, Beijing 100045, China. Wujie_0901@163.com
Received: August 3, 2023
Peer-review started: August 3, 2023
First decision: August 16, 2023
Revised: August 24, 2023
Accepted: September 6, 2023
Article in press: September 6, 2023
Published online: October 27, 2023
Abstract
BACKGROUND

This study evaluated the safety and effectiveness of endoscopic retrograde cholangiopancreatography (ERCP) in pediatric patients with biliary and pancreatic diseases. A retrospective analysis was conducted on 57 ERCP procedures performed in 41 children, primarily for treating pancreatic diseases. The overall success rate was 91.2%, with no major complications observed. Post-ERCP pancreatitis (PEP) occurred in 8.8% of cases. Follow-up examinations over one year showed no recurrence of biliary or pancreatic diseases. Notably, endoscopic treatment led to a significant increase in body mass index (BMI). These findings demonstrate the valuable role of ERCP in managing such conditions.

AIM

To evaluate the safety and efficacy of ERCP for the management of biliary and pancreatic diseases in pediatric patients.

METHODS

We conducted a retrospective analysis of data from children aged 1-18 years who underwent ERCP for biliary and pancreatic diseases at Beijing Children’s Hospital between January 2021 and December 2022. The collected data included procedure time, endoscopic treatment, success rate, and postoperative complications.

RESULTS

Forty-one children underwent 57 ERCP procedures, including 14 with biliary duct disease and 27 with pancreatic disease. The mean age of the patients was 7.48 ± 3.48 years. Biliary duct-related treatments were performed 18 times, and pancreatic disease treatments were performed 39 times. ERCP was primarily used to treat pediatric pancreatic diseases [68.4% (39/57) of the procedures]. The overall success rate was 91.2% (52/57 patients). PEP was noted in five patients (8.8%, 5/57), and no instances of bleeding, perforation, or cholangitis were observed. The patients were followed up for over one year, and no recurrence of biliary or pancreatic diseases was detected. Importantly, BMI significantly increased after endoscopic treatment compared to that before treatment (P = 0.001).

CONCLUSION

The high success rate and lack of major complications support the valuable role of ERCP in the management of pediatric biliary and pancreatic diseases in the pediatric population.

Keywords: Pediatric, Endoscopic retrograde cholangiopancreatography, Choledocholithiasis, Chronic pancreatitis, Pancreatic ducts, Postoperative complications

Core Tip: We evaluated the safety and efficacy of endoscopic retrograde cholangiopancreatography (ERCP) in pediatric patients with biliary and pancreatic diseases. In total, 57 ERCP procedures were performed in 41 children, primarily for the treatment of pancreatic diseases. The overall success rate was 91.2% with no instances of bleeding, perforation, or cholangitis. Post-ERCP pancreatitis occurred in 8.8% of the cases. The patients were followed up for over one year, and no recurrence of biliary or pancreatic diseases was detected. Importantly, endoscopic treatment significantly increased body mass index. These findings highlighted the valuable role of ERCP in managing these conditions.